The companies collaborated on the development of NM-01 which can be labeled with radioisotopes for multiple tumor types. Both the companies get the option to expand the collaboration on additional assets along with license rights in Radiopharm’s pipeline
Lantheus retains an exclusive imaging right to NM-01 (Ex- China) & initiated the P-II trial of NM-01 in NSCLC. The P-I therapeutic trial will be initiated in Australia for PD-L1 + NSCLC
Both the companies will cross-reference their data to advance PD-L1 assets, incl. the development & regulatory process with the US FDA & other regulatory agencies. Under a separate agreement with NanoMab, Radiopharm gets imaging rights of NM-01 in China & global IP rights for therapeutic use
Ref: PR Newswire | Image: Radiopharm
